AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) General Information
Description
The commercial rights to Arimidex (anastrozole) and Casodex (bicalutamide) in various European and African countries.
Contact Information
Corporate Office
- Cambridge
- England, United Kingdom
Corporate Office
- Cambridge
- England, United Kingdom
AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) FAQs
-
Where is AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) headquartered?
AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) is headquartered in Cambridge, United Kingdom.
-
What industry is AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) in?
AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries)’s primary industry is Buildings and Property.
-
Is AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) a private or public company?
AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) is a Private company.
-
What is the current valuation of AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries)?
The current valuation of AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) is .
-
What is AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries)’s current revenue?
The current revenue for AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) is .
-
Who are AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries)’s investors?
AstraZeneca has invested in AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries).
-
When was AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) acquired?
AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) was acquired on 20-Dec-2019.
-
Who acquired AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries)?
AstraZeneca (Arimidex and Casodex Commercial Rights in European and African Countries) was acquired by Juvise Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process